Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 7/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513263 | 0.93 | MAPT (0.53) | MAPTMAPK1LMNAGRM5CYP1A2 | |
| SCHEMBL513522 | 0.88 | LMNA (0.55) | MAPTMAPK1LMNAGRM5CYP1A2 | |
| SCHEMBL513696 | 0.83 | GRM5 (0.55) | MAPTMAPK1LMNAGRM5CYP1A2 | |
| SCHEMBL512252 | 0.83 | GRM5 (0.56) | MAPTMAPK1LMNAGRM5CYP1A2 | |
| SCHEMBL513226 | 0.81 | GRM5 (0.52) | MAPTMAPK1LMNAGRM5CYP1A2 | |
| SCHEMBL512619 | 0.74 | GRM5 (0.46) | MAPTMAPK1LMNAGRM5CYP1A2 | |
| SCHEMBL513164 | 0.72 | LMNA (0.49) | MAPTMAPK1LMNAGRM5CYP1A2 | |
| SCHEMBL514927 | 0.72 | MAPT (0.37) | MAPTMAPK1LMNAGRM5ALDH1A1 | |
| SCHEMBL512929 | 0.72 | GRM5 (0.42) | MAPTMAPK1LMNAGRM5ALDH1A1 | |
| SCHEMBL3642550 | 0.71 | GRM5 (0.77) | MAPTMAPK1LMNAGRM5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | claimed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | claimed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | MAPT 2573/4885MAPK1 3316/4885LMNA 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.